Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31539171 | 0.86 | TARBP2 (0.47) | KDM4ERAB9ANPC1TARBP2HPGD | |
| SCHEMBL17540833 | 0.86 | KDM4E (0.49) | KDM4ERAB9ANPC1TARBP2HPGD | |
| SCHEMBL27536014 | 0.85 | KDM4E (0.49) | KDM4ERAB9ANPC1TARBP2HPGD | |
| SCHEMBL7083110 | 0.83 | NPC1 (0.43) | KDM4ERAB9ANPC1HPGDGAA | |
| SCHEMBL5721821 | 0.83 | ALDH1A1 (0.50) | KDM4ERAB9ANPC1HPGDPPARG | |
| SCHEMBL7737637 | 0.83 | KDM4E (0.46) | KDM4ERAB9ANPC1TARBP2HPGD | |
| SCHEMBL5123679 | 0.82 | NPC1 (0.48) | KDM4ERAB9ANPC1GAAPPARG | |
| SCHEMBL7737616 | 0.81 | MAPT (0.40) | KDM4ERAB9ANPC1HPGDGAA | |
| SCHEMBL18924759 | 0.80 | KDM4E (0.48) | KDM4ERAB9ANPC1TARBP2HPGD | |
| SCHEMBL10480745 | 0.80 | SMN1; SMN2 (0.46) | KDM4ERAB9ANPC1TARBP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-7084162-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-7053106-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1231482-C | Process for preparing thiazolidinedione derivatives and intermediates | HOFFMANN LA ROCHE (CH) | 2005-12-14 | — | — | CN | disclosed |
| EP-1589006-A1 | Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents | Bristol-Myers Squibb Company (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6919358-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-5728720-A | HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; TREATMENT OF DIABETES | JAPAN TOBACCO INC. (JP) | 1998-03-17 | — | — | US | disclosed |
| WO-1997000249-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-03 | — | — | WO | disclosed |
| CN-1129698-A | Oxazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-08-28 | — | — | CN | disclosed |
| US-5541205-A | ANTIINFLAMMATORY AGENTS; ANTIASTHMA AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0710659-A1 | Oxazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5498621-A | Oxazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5428048-A | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0428312-B1 | Oxazolidinedione hypoglycemic agents | PFIZER (US) | 1994-12-28 | — | — | EP | disclosed |
| WO-1991007107-A1 | OXAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| EP-0428312-A2 | Oxazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | KDM4E 2164/4885RAB9A 1112/4885NPC1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.